Martin Aringer

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. ncbi request reprint [Systemic lupus erythematosus--activity and outcome]
    M Aringer
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:103-6, 108-9. 2006
  2. ncbi request reprint Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
    Martin Aringer
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:274-9. 2007
  3. ncbi request reprint ICF core sets: how to specify impairment and function in systemic lupus erythematosus
    M Aringer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Lupus 15:248-53. 2006
  4. ncbi request reprint Cytokine expression in lupus kidneys
    M Aringer
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Lupus 14:13-8. 2005
  5. ncbi request reprint Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study
    Martin Aringer
    Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 50:3161-9. 2004
  6. doi request reprint Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells
    Thomas Karonitsch
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 60:1463-71. 2009
  7. doi request reprint Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise
    Bettina Bauernfeind
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 61:21-8. 2009
  8. doi request reprint Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis
    Thomas Karonitsch
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 64:400-8. 2012
  9. ncbi request reprint Does mixed connective tissue disease exist? Yes
    Martin Aringer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 31:411-20, v. 2005
  10. ncbi request reprint Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status
    Tanja A Stamm
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 57:1287-95. 2007

Collaborators

Detail Information

Publications32

  1. ncbi request reprint [Systemic lupus erythematosus--activity and outcome]
    M Aringer
    Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
    Z Rheumatol 65:103-6, 108-9. 2006
    ..The combination of shorter studies for defining hopeful strategies followed by long definitive studies, appears to be the best option at present...
  2. ncbi request reprint Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
    Martin Aringer
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:274-9. 2007
    ..To analyze changes in autoantibodies occurring in patients with systemic lupus erythematosus (SLE) treated with 4 infusions of the chimeric anti-tumor necrosis factor alpha (TNFalpha) antibody infliximab...
  3. ncbi request reprint ICF core sets: how to specify impairment and function in systemic lupus erythematosus
    M Aringer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Lupus 15:248-53. 2006
    ..The development of these SLE ICF Core Sets is designed to be an inclusive, open, worldwide process. We therefore invite both SLE clinical experts and SLE patients to participate actively...
  4. ncbi request reprint Cytokine expression in lupus kidneys
    M Aringer
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Lupus 14:13-8. 2005
    ..This may help solve discrepancies between different murine models of the disease and provide a better rationale for targeting certain cytokines in human SLE...
  5. ncbi request reprint Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study
    Martin Aringer
    Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 50:3161-9. 2004
    ....
  6. doi request reprint Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells
    Thomas Karonitsch
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 60:1463-71. 2009
    ....
  7. doi request reprint Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise
    Bettina Bauernfeind
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 61:21-8. 2009
    ..To identify the most important and relevant concepts of daily functioning from the perspective of patients with systemic lupus erythematosus (SLE)...
  8. doi request reprint Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis
    Thomas Karonitsch
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 64:400-8. 2012
    ..The aim of this study was to determine the systemic activity of the IFN/STAT-1 signaling pathway in the peripheral blood cells of patients with RA...
  9. ncbi request reprint Does mixed connective tissue disease exist? Yes
    Martin Aringer
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 31:411-20, v. 2005
    ..The authors believe that the concept is useful in daily practice and accurate in the idea that MCTD constitutes a disease entity of its own...
  10. ncbi request reprint Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status
    Tanja A Stamm
    Vienna Medical University, Vienna, Austria
    Arthritis Rheum 57:1287-95. 2007
    ..To explore the array of concepts important to patients with chronic systemic lupus erythematosus (SLE) and to compare these with instruments assessing disease activity, damage, and health status...
  11. ncbi request reprint Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon
    Eva Feierl
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Autoimmunity 40:315-21. 2007
    ....
  12. ncbi request reprint Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy
    Georg H Stummvoll
    Deptartment of Rheumatology, University of Vienna, Vienna General Hospital, Vienna, Austria
    Wien Klin Wochenschr 116:716-24. 2004
    ..Immunoadsorption (IAS), in contrast, selectively removes Ig and IC and may thus be safer. We therefore investigated the rate of infections in SLE patients who were undergoing long-term IAS...
  13. pmc Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature
    Georg Schett
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    J Clin Microbiol 43:2537-41. 2005
    ..We review the literature of articular listeriosis and discuss the role of tumor necrosis factor blockade in precipitating listeriosis...
  14. ncbi request reprint Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings
    Claudia Schueller-Weidekamm
    Department of Diagnostic Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Eur J Radiol 62:437-43. 2007
    ..To explore the typical sonographic features of gray-scale and Power Doppler of acute and chronic gouty arthritis in conjunction with radiographic, clinical, and laboratory findings...
  15. pmc IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study
    G H Stummvoll
    Department of Rheumatology, Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 64:1015-21. 2005
    ....
  16. ncbi request reprint Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention
    M Aringer
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Lupus 13:344-7. 2004
    ..Interferon (IFN)-gamma, interleukin (IL)-18, IL-6 and possibly IL-1 are increased in SLE and likewise involved in the inflammatory process. Specific therapeutic agents for blocking these cytokines should be available in the near future...
  17. pmc SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus
    Martin Aringer
    Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
    Arthritis Res Ther 5:172-7. 2003
    ..Therefore, TNF blockade probably constitutes an efficacious therapeutic option...
  18. ncbi request reprint Anti-cytokine therapy in systemic lupus erythematosus
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lupus 14:189-91. 2005
    ..Since new therapeutic agents may soon offer many ways to influence the process, controlled clinical trials following open-label safety studies are of central importance to arrive at optimized therapies for SLE patients...
  19. doi request reprint Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus
    G H Stummvoll
    G Steiner, Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
    Ann Rheum Dis 68:110-6. 2009
    ....
  20. ncbi request reprint Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death
    M Aringer
    Department of Rheumatology, Internal Medicine II, University of Vienna, Austria
    Lupus 11:102-8. 2002
    ..Peripheral blood lymphocytes of SLE patients express functional TNF receptors. Finally, associations with cell death and CD95 receptors suggest that TNF may be pathogenic in SLE...
  21. ncbi request reprint Serum interleukin-15 is elevated in systemic lupus erythematosus
    M Aringer
    Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
    Rheumatology (Oxford) 40:876-81. 2001
    ..Both lymphocyte CD25 and Bcl-2 expression significantly correlated with serum IL-15 and were increased by recombinant IL-15. CONCLUSION: Serum IL-15 may in part be responsible for the immunological abnormalities seen in active SLE...
  22. ncbi request reprint Periodic fever syndromes--a clinical overview
    Martin Aringer
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Acta Med Austriaca 31:8-12. 2004
    ..Therefore this review will concentrate on FMF and TRAPS, the latter being a very rare disease, while the former has become somewhat more common in mid-Europe as a result of migration...
  23. pmc High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers
    Josef Hermann
    Ann Rheum Dis 66:561-2. 2007
  24. pmc The role of tumor necrosis factor-alpha in systemic lupus erythematosus
    Martin Aringer
    Division of Rheumatology, Department of Medicine III, University Clinical Center Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Arthritis Res Ther 10:202. 2008
    ..At the same time, open-label data suggest that TNF blockade suppresses inflammatory manifestations of SLE, and long-term benefit was seen in patients with lupus nephritis. A controlled clinical trial is under way...
  25. ncbi request reprint Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation
    Johannes Grisar
    Department of Internal Medicine III, University of Vienna, Austria
    J Rheumatol 29:1430-6. 2002
    ..To test if markers of bone metabolism are altered in patients with seronegative spondyloarthropathies (SSpA)...
  26. ncbi request reprint Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus
    Martin Aringer
    University Clinical Center Carl Gustav Carus, Technical University of Dresden, Division of Rheumatology, Department of Medicine III, Fetscherstrasse 74, 01307 Dresden, Germany
    Expert Opin Drug Saf 7:411-9. 2008
    ..There is still unmet medical need in the therapy of severe organ manifestations of patients with systemic lupus erythematosus (SLE). Therapeutic agents targeting pro-inflammatory cytokines may be an interesting option...
  27. ncbi request reprint Engineering anticancer T cells for extended functional longevity
    Graham Pawelec
    Center for Medical Research, ZMF, University of Tubingen Medical School, Waldhornlestrasse 22, D 72072 Tuebingen, Germany
    Ann N Y Acad Sci 1019:178-85. 2004
    ....
  28. doi request reprint Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and co
    Esther Jimenez-Boj
    Technical University Dresden, Dresden, Germany
    Arthritis Rheum 58:1226-36. 2008
    ....
  29. ncbi request reprint New treatments for SLE: cell-depleting and anti-cytokine therapies
    Jennifer H Anolik
    Allergy, Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Best Pract Res Clin Rheumatol 19:859-78. 2005
    ..Moreover, many additional cytokines, such as interleukin (IL)-6, IL-18, and the type I interferons, represent interesting future targets...
  30. doi request reprint SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout
    Veronique Vitart
    MRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, UK
    Nat Genet 40:437-42. 2008
    ..SLC2A9 is a known fructose transporter, and we now show that it has strong uric acid transport activity in Xenopus laevis oocytes...
  31. ncbi request reprint [Cyclooxygenase 2 selective antirheumatic analgesics]
    Martin Aringer
    Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Wahringer Gurtel 18 20, A 1090 Wien
    Wien Med Wochenschr 153:100-3. 2003
    ..5 mg is sufficient for the control of less pronounced pain and thus not exceeded. The gastrointestinal safety of nimesulide can not be sufficiently evaluated based on the available clinical data...
  32. pmc The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis
    Laszlo Czirjak
    Department of Immunology and Rheumatology, University of Pecs, H 7621 Pecs, Irgalmasok u 1, Hungary
    Ann Rheum Dis 66:966-9. 2007
    ..To evaluate the ability to teach scleroderma experts and young rheumatologists to perform the modified Rodnan skin score test...